Trophoblast retrieval and isolation from the cervix (TRIC) may one day lead to early identification of fetal genetic disorders.
Isolation and analysis of trophoblast cells that carry fetal DNA may be possible as early as 5 weeks’ gestation, according to researchers from Wayne State University. Reporting in Science Translational Medicine, they describe results of a small proof-of-concept study of next-generation sequencing of cells obtained noninvasively from Pap smears.
Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the research may lead to clinical trials of the technique, called trophoblast retrieval and isolation from the cervix (TRIC). The next step, says the authors, is to determine whether TRIC can identify genetic disorders in a fetus.
For the proof-of-concept work, the researchers were able to isolate intact trophoblast cells from Pap smears collected noninvasively at 5 to 19 weeks’ gestation for next-generation sequencing of fetal DNA. Profiling of 20 consecutive matched maternal, placental, and fetal samples was performed with multiplex targeted DNA sequencing of 59 short tandem repeat and 94 single-nucleotide variant sites across all 24 chromosomes. The data revealed fetal DNA fractions of 85% to 99.9%, with 100% correct fetal haplotyping with minimal maternal DNA contamination.
“We used next-generation sequencing and accurately determined the nucleotide sequence down to a single base,” said co-principal investigator Sascha Drewlo, PhD, in a press release. “TRIC could be used as a noninvasive test, with the accuracy of invasive tests like amniocentesis, and the ability to perform the test 5 to 10 weeks earlier than current testing modalities.”
Maternal sFLT1 and EDN1 linked to late-onset preeclampsia
November 25th 2024A new study highlights the association of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 with preeclampsia severity, offering insights into the pathogenesis of early- and late-onset forms of the condition.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More